Login to Your Account



Exelixis Turns X-Ceptor Into Partners: Third Deal Signed

By Karen Pihl-Carey


Tuesday, March 21, 2006
About 18 months ago, South San Francisco-based Exelixis Inc. made a $25.7 million investment when it acquired three preclinical programs through its buyout of X-Ceptor Therapeutics Inc. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription